Open AccessA Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection
Author(s) -
Mark A. Jacobson,
John Spritzler,
Alan Landay,
Ellen S. Chan,
David Katzenstein,
Barbara Schock,
Lawrence Fox,
Joana D'Arc Roe,
Smriti K. Kundu,
Richard B. Pollard
Publication year - 2002
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/00002030-200205240-00008
Subject(s) - neopterin , medicine , immunology , peripheral blood mononuclear cell , immune system , immunopathology , interleukin 2 , lymphocyte , cellular immunity , cytokine , placebo , biology , in vitro , pathology , biochemistry , alternative medicine
Interleukin (IL)-12 is a cytokine that stimulates T lymphocytes and natural killer cells to generate a Type 1 T-helper lymphocyte immune response. The primary objective of this study was to determine the safety and immunologic activity of repeated recombinant human IL-12 (rhIL-12) dosing in HIV-infected patients over a broad range of the HIV disease spectrum.